

FORM PTO-1449
(REV. 7-85)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. PH-7382-NP

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

APPLICATION NO. 10/650,358

APPLICANT Michael G. Yang

FILING DATE 27 Aug 2003

DEC 15 2003
PTAB/USPTO

PATENT & TRADEMARK OFFICE

U.S. PATENT DOCUMENTS

EXAMINEE R INITIAL		DOCUMENT NUMBER	TRADEMARK NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA							
	AB							

FOREIGN PATENT DOCUMENTS

	AC	DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION YES	TRANSLATION NO
	AD	WO 00/07995	17 Feb 2000	DU PONT PHARMACEUTICALS CO.	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AE	WO 01/77086	18 Oct 2001	DU PONT PHARMACEUTICALS CO.	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AF	WO 00/38618	6 July 2000	DU PONT PHARMACEUTICALS CO.	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AG	WO 01/92235	6 Dec 2001	DU PONT PHARMACEUTICALS CO.	—	—	<input type="checkbox"/>	<input type="checkbox"/>
	AH						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AI	CHAPMAN, P. F., <i>et al.</i> , "Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice", <i>Nature Neurosci.</i> (1999), 2, 271-276
	AJ	DAHLGREN, K. N., <i>et al.</i> , "Oligomeric and Fibrillar Species of Amyloid- β Peptides Differentially Affect Neuronal Viability", <i>J. Biol. Chem.</i> (2002) 277, 32046-32053
	AK	GÖTZ, J., <i>et al.</i> , "Formation of Neurofibrillary Tangles in P301L Tau Transgenic Mice Induced by A β 42 Fibrils", <i>Science</i> (2001) 293, 1491-1495
	AL	LEWIS, J., <i>et al.</i> , "Enhanced Neurofibrillary Degeneration in Transgenic Mice Expressing Mutant Tau and APP", <i>Science</i> (2001), 293, 1487-1491
	AM	MCLEAN, C. A., <i>et al.</i> , "Soluble pool of A β -amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease", <i>Ann. Neurol.</i> (1999) 46, 860-866
	AN	SEIFFERT, D. F., <i>et al.</i> , "Presenilin-1 and -2 Are Molecular Targets for γ -Secretase Inhibitors", <i>J. Biol. Chem.</i> (2000) 275, 34086-34091
	AO	SELKOE, D. J., "Alzheimer's Disease: Genes, Proteins, & Therapy", <i>Physiol. Rev.</i> (2001) 81, 741-766
	AP	SELKOE, D. J., ".Mechanism of Alzheimer's Disease", <i>Ann. Rev. Cell Biol.</i> (1994) 10: 373-403
	AQ	THAL, D. R., <i>et al.</i> , "Two Types of Sporadic Cerebral Amyloid Angiopathy", <i>J. Neuropath. Exp. Neuro.</i> (2002) 61: 82-293
	AR	WALSH, D. M., <i>et al.</i> , "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation <i>in vivo</i> ", <i>Nature</i> (2002) 416, 535-539
	AS	WOLFE, M. S., "Secretase Targets for Alzheimer's Disease: Identification and Therapeutic Potential", <i>J. Med. Chem.</i> (2001) 44, 2039-2060
	AT	

EXAMINER	DATE CONSIDERED
<i>Mark Sackay</i>	9/23/05

*EXAMINER: Initial of reference considered/whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.